BMY, Emory University Join Forces - Analyst Blog

By
A A A

Recently, Bristol-Myers Squibb Company ( BMY ) inked a deal with Emory University for the development of the former's pipeline candidates primarily in the fields of oncology, metabolics, hepatitis C and immunoscience.

Per the agreement, Emory University will be responsible for conducting phase II, phase III and pediatric studies in metropolitan Atlanta for the development of Bristol-Myers' pipeline. The initial focus of the deal would be to develop the oncology pipeline at Bristol-Myers.

We note that Emory University is a well established educational and research institution including nine highly ranked colleges and professional schools. Moreover, the University boasts of a comprehensive health system.

Our Recommendation

We currently have a Neutral recommendation on Bristol-Myers. The stock carries a Zacks #3 Rank (Hold rating) in the short run. We believe that investor focus will remain on how Bristol-Myers fares following the US loss of exclusivity of its blockbuster blood thinner Plavix on May 17, 2012.

Bristol-Myers has co-developed Plavix with Sanofi ( SNY ). The loss of exclusivity is likely to result in substantial revenue losses for Bristol-Myers. Companies such as Mylan Inc. ( MYL ) and Dr. Reddy's Laboratories ( RDY ) have already launched their respective generic versions of the drug.

Bristol-Myers is looking to combat the generic threat through partnering deals and acquisitions. Apart from acquisitions and partnership deals, Bristol-Myers is looking to introduce new products to augment its product portfolio to combat the generic threat. Bristol-Myers has met with a fair amount of success towards achieving this objective. Many new products were launched/ approved in 2011. We expect Bristol-Myers to continue introducing new products throughout 2012.


 
BRISTOL-MYERS (BMY): Free Stock Analysis Report
 
MYLAN INC (MYL): Free Stock Analysis Report
 
DOCTOR REDDYS (RDY): Free Stock Analysis Report
 
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: BMY , MYL , RDY , SNY

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

183,639,073
  • $42.32 ▲ 3.85%
82,623,623
  • $15.99 ▼ 22.79%
39,547,942
  • $119 ▲ 1.19%
32,107,751
  • $77.62 ▲ 2.63%
29,684,848
  • $10.60 ▲ 2.02%
27,615,309
  • $24.03 ▲ 0.38%
26,917,669
  • $31.10 ▲ 2.07%
26,464,306
  • $47.75 ▲ 0.59%
As of 11/26/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com